Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 230

Results For "THA"

8072 News Found

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer
Clinical Trials | July 03, 2025

RedHill Biopharma initiates Expanded Phase 2 Study combining Opaganib and Darolutamide in advanced prostate cancer

Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.


Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability
News | July 03, 2025

Mitsui Chemicals launches InnoCell cell Culture microplates with exceptional oxygen permeability

InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services


Cadila Pharmaceuticals launches Bilacad Dex Syrup
News | July 02, 2025

Cadila Pharmaceuticals launches Bilacad Dex Syrup

A triple-action Formula for comprehensive respiratory relief


AstraZeneca Pharma India receives permission to import Durvalumab Solution
News | July 02, 2025

AstraZeneca Pharma India receives permission to import Durvalumab Solution

Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy


INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease
Clinical Trials | July 02, 2025

INmune Bio reports core findings from Phase 2 trial in early Alzheimer’s disease

Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients


Glaukos receives EU MDR certification for iStent infinite
Medical Device | July 02, 2025

Glaukos receives EU MDR certification for iStent infinite

The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma


AbbVie to acquire Capstan Therapeutics for $2.1 billion
Biotech | July 01, 2025

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo


Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery
Digitisation | July 01, 2025

Pfizer strengthens AI collaboration with XtalPi to accelerate drug discovery

The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development


Briefs: Lyfius Pharma and Aurobindo Pharma
News | July 01, 2025

Briefs: Lyfius Pharma and Aurobindo Pharma

Lyfius Pharma restarts operations at Penicillin-G manufacturing facility